Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Next Generation Drug Conjugates Global Market Report 2025
Request Sample Buy Now
Global Next Generation Drug Conjugates Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Next Generation Drug Conjugates Global Market Report 2025

By Next-Generation Drug Conjugates Type (Peptide Receptor Radionuclide Therapy, Ligand Mediated RNAI Conjugate, Ligand Conjugated Anti Sense Medicine, Peptide Drug Conjugate), By Targeting Ligand Type (Amino Sugar, Lipid, Peptide, Small Molecule, Virus-Like Particles), By Payload Type (Oligonucleotide, Radionuclide, Peptide, Small Molecule), By Therapy (Monotherapy, Combination Therapy), By Indication (Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Other Indications) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Next Generation Drug Conjugates Market Overview

• Next Generation Drug Conjugates market size has reached to $2.15 billion in 2024

• Expected to grow to $4.41 billion in 2029 at a compound annual growth rate (CAGR) of 15.6%

• Growth Driver: Rising Prevalence Of Cancer Is Driving The Growth Of The Next Generation Drug Conjugates Market

• Market Trend: Strategic Partnerships Driving Innovation In Next-Generation Drug Conjugates

• North America was the largest region in 2024.

What Is Covered Under Next Generation Drug Conjugates Market?

Next-generation drug conjugates refer to advanced formulations of drug conjugates designed to improve the efficacy and safety of targeted therapies. Next-generation drug conjugates utilize advanced targeting technologies and enhanced payloads to deliver potent therapies directly to disease cells with greater precision and reduced side effects.

The main types of next-generation drug conjugates are peptide receptor radionuclide therapy, ligand mediated RNAI conjugate, ligand conjugated anti sense medicine, and peptide drug conjugate. Peptide Receptor Radionuclide Therapy (PRRT) is a targeted cancer treatment that uses radioactive peptides to bind to and destroy tumor cells expressing specific receptors. The targeting ligands include amino sugars, lipids, peptides, small molecules, and virus-like particles, with payload types such as oligonucleotides, radionuclides, peptides, and small molecules. The therapy can be administered as monotherapy or combination therapy for various indications, including gastroenteropancreatic neuroendocrine tumors, prostate cancer, leptomeningeal carcinomatosis caused by breast cancer brain metastases, hereditary transthyretin amyloidosis, atherosclerotic cardiovascular diseases, severe hypertriglyceridemia, hereditary angioedema, acute hepatic porphyria, and others.

Next Generation Drug Conjugates Market Size and growth rate 2025 to 2029: Graph

What Is The Next Generation Drug Conjugates Market Size 2025 And Growth Rate?

The next generation drug conjugates market size has grown rapidly in recent years. It will grow from $2.15 billion in 2024 to $2.47 billion in 2025 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to an increasing understanding of tumor biology, the success of early drug conjugates, increasing oncology, increasing investment and funding, and increasing patient advocacy and awareness.

What Is The Next Generation Drug Conjugates Market Growth Forecast?

The next generation drug conjugates market size is expected to see rapid growth in the next few years. It will grow to $4.41 billion in 2029 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to the growth of combination therapies, clinical research expansion, focus on rare diseases, strategic collaborations, and emerging bioinformatics tools. Major trends in the forecast period include advancements in monoclonal antibody technology, combination therapies with JAK inhibitors, artificial intelligence in drug development, development of biosimilars, and advancements in subcutaneous formulations.

The forecast of 15.6% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations could burden U.S. oncology research by driving up prices of novel antibody-drug conjugates and peptide-drug conjugates sourced from Germany and South Korea, resulting in delayed targeted cancer therapy development and higher precision medicine research and development expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Next Generation Drug Conjugates Market Segmented?

1) By Next-Generation Drug Conjugates Type: Peptide Receptor Radionuclide Therapy, Ligand Mediated RNAI Conjugate, Ligand Conjugated Anti Sense Medicine, Peptide Drug Conjugate

2) By Targeting Ligand Type: Amino Sugar, Lipid, Peptide, Small Molecule, Virus-Like Particles

3) By Payload Type: Oligonucleotide, Radionuclide, Peptide, Small Molecule

4) By Therapy: Monotherapy, Combination Therapy

5) By Indication: Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Other Indications

Subsegments:

1) By Peptide Receptor Radionuclide Therapy (PRRT): Somatostatin Analogues, Radiolabeled Peptides

2) By Ligand Mediated RNAi Conjugate: SiRNA Ligand Conjugates, ShRNA Ligand Conjugates

3) By Ligand Conjugated Anti-Sense Medicine: Oligonucleotide Ligand Conjugates, Antisense Oligonucleotide Ligand Conjugates

4) By Peptide Drug Conjugate: Cytotoxic Peptide Conjugates, Therapeutic Peptide Conjugates

What Is Driving The Next Generation Drug Conjugates Market? Rising Prevalence Of Cancer Is Driving The Growth Of The Next Generation Drug Conjugates Market

The rising prevalence of cancer is expected to propel the growth of the next-generation drug conjugates market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rise in cancer incidence is primarily due to an aging population, lifestyle factors, environmental exposures, improved detection, genetic factors, and infectious agents. Next-generation drug conjugates help mitigate cancer by delivering targeted therapies directly to cancer cells, enhancing treatment efficacy while minimizing damage to healthy tissues. For instance, in August 2024, according to a report published by the Australian Institute of Health and Welfare, an Australia-based national agency for information and statistics on Australia's health and welfare., by 2034, Australia is projected to have approximately 209,000 new cancer diagnoses, a significant increase from the estimated 169,000 cases expected in 2024, reflecting the impact of a growing population and rising cancer rates. Therefore, the rising prevalence of cancer is driving the growth of the next-generation drug conjugates market.

Who Are The Major Players In The Global Next Generation Drug Conjugates Market?

Major companies operating in the next generation drug conjugates marker are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Daiichi Sankyo Company Limited, Eisai Co Ltd., Bicycle Therapeutics plc, Zymeworks Inc., Genentech Inc., MacroGenics Inc., Abzena plc, Innate Pharma S.A., CytomX Therapeutics Inc., ImmunoGen Inc., Ascentage Pharma Group International, Mersana Therapeutics Inc., Antengene Corporation Limited, Nurix Therapeutics Inc., Tubulis GmbH

What Are The Key Trends Of The Global Next Generation Drug Conjugates Market? Strategic Partnerships Driving Innovation In Next-Generation Drug Conjugates

Major companies operating in the next-generation drug conjugates market are adopting a strategic partnerships approach to enhance research and development capabilities, accelerate product innovation, and expand their market presence. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in November 2023, Prelude Therapeutics Incorporated, a US-based clinical-stage precision oncology company, partnered with AbCellera Biologics Inc., a Canada-based biotechnology company, to develop first-in-class precision antibody-drug conjugates (ADCs) for oncology. The partnership will concentrate on the discovery, development, and commercialization of innovative antibody-drug conjugates (ADCs), starting with a program that targets a SMARCA degrader linked to a novel antibody. This strategy aims to broaden the therapeutic applications of Prelude's small-molecule SMARCA2 selective degraders to a wider patient population, especially those with cancers unrelated to SMARCA4 mutations.

Need data on a specific region in this market?
Request Customisation

What Are Latest Mergers And Acquisitions In The Next Generation Drug Conjugates Market? Johnson & Johnson Expands Oncology Portfolio With Ambrx Biopharma Acquisition

In March 2024, Johnson & Johnson, a US-based manufacturer of pharmaceutical products and medical devices, acquired Ambrx Biopharma for $2 billion. Through this acquisition, Johnson & Johnson aims to enhance its oncology portfolio and advance the development of next-generation antibody drug conjugates aimed at transforming cancer treatment. Ambrx Biopharma is a US-based clinical-stage biopharmaceutical company and involves next-generation drug conjugates.

What Is The Regional Outlook For The Global Next Generation Drug Conjugates Market?

North America was the largest region in the next generation drug conjugates market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Next Generation Drug Conjugates Market?

The next-generation drug conjugates market consists of revenues earned by entities by providing services such as targeted cancer therapies, gene therapy conjugates, and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation drug conjugates market also includes sales of small molecule drug conjugates, RNA-targeted conjugates, and enzyme-linked drug conjugates. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Next Generation Drug Conjugates Industry?

The next generation drug conjugates market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the next generation drug conjugates industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Next Generation Drug Conjugates Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $2.47 billion
Revenue Forecast In 2034 $4.41 billion
Growth Rate CAGR of 15.6% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Next-Generation Drug Conjugates Type: Peptide Receptor Radionuclide Therapy, Ligand Mediated RNAI Conjugate, Ligand Conjugated Anti Sense Medicine, Peptide Drug Conjugate
2) By Targeting Ligand Type: Amino Sugar, Lipid, Peptide, Small Molecule, Virus-Like Particles
3) By Payload Type: Oligonucleotide, Radionuclide, Peptide, Small Molecule
4) By Therapy: Monotherapy, Combination Therapy
5) By Indication: Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Other Indications Subsegments: 1) By Peptide Receptor Radionuclide Therapy (PRRT): Somatostatin Analogues, Radiolabeled Peptides
2) By Ligand Mediated RNAi Conjugate: SiRNA Ligand Conjugates, ShRNA Ligand Conjugates
3) By Ligand Conjugated Anti-Sense Medicine: Oligonucleotide Ligand Conjugates, Antisense Oligonucleotide Ligand Conjugates
4) By Peptide Drug Conjugate: Cytotoxic Peptide Conjugates, Therapeutic Peptide Conjugates
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Daiichi Sankyo Company Limited, Eisai Co Ltd., Bicycle Therapeutics plc, Zymeworks Inc., Genentech Inc., MacroGenics Inc., Abzena plc, Innate Pharma S.A., CytomX Therapeutics Inc., ImmunoGen Inc., Ascentage Pharma Group International, Mersana Therapeutics Inc., Antengene Corporation Limited, Nurix Therapeutics Inc., Tubulis GmbH
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Next Generation Drug Conjugates Market Characteristics

3. Next Generation Drug Conjugates Market Trends And Strategies

4. Next Generation Drug Conjugates Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Next Generation Drug Conjugates Growth Analysis And Strategic Analysis Framework

5.1. Global Next Generation Drug Conjugates PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Next Generation Drug Conjugates Market Growth Rate Analysis

5.4. Global Next Generation Drug Conjugates Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Next Generation Drug Conjugates Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Next Generation Drug Conjugates Total Addressable Market (TAM)

6. Next Generation Drug Conjugates Market Segmentation

6.1. Global Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Peptide Receptor Radionuclide Therapy

Ligand Mediated RNAI Conjugate

Ligand Conjugated Anti Sense Medicine

Peptide Drug Conjugate

6.2. Global Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Amino Sugar

Lipid

Peptide

Small Molecule

Virus-Like Particles

6.3. Global Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oligonucleotide

Radionuclide

Peptide

Small Molecule

6.4. Global Next Generation Drug Conjugates Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monotherapy

Combination Therapy

6.5. Global Next Generation Drug Conjugates Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Gastroenteropancreatic Neuroendocrine Tumors

Prostate Cancer

Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases

Hereditary Transthyretin Amyloidosis

Atherosclerotic Cardiovascular Diseases

Severe Hypertriglyceridemia

Hereditary Angioedema

Acute Hepatic Porphyria

Other Indications

6.6. Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Peptide Receptor Radionuclide Therapy (PRRT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Somatostatin Analogues

Radiolabeled Peptides

6.7. Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Ligand Mediated RNAi Conjugate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

SiRNA Ligand Conjugates

ShRNA Ligand Conjugates

6.8. Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Ligand Conjugated Anti-Sense Medicine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oligonucleotide Ligand Conjugates

Antisense Oligonucleotide Ligand Conjugates

6.9. Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Peptide Drug Conjugate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Cytotoxic Peptide Conjugates

Therapeutic Peptide Conjugates

7. Next Generation Drug Conjugates Market Regional And Country Analysis

7.1. Global Next Generation Drug Conjugates Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Next Generation Drug Conjugates Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Next Generation Drug Conjugates Market

8.1. Asia-Pacific Next Generation Drug Conjugates Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Next Generation Drug Conjugates Market

9.1. China Next Generation Drug Conjugates Market Overview

9.2. China Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Next Generation Drug Conjugates Market

10.1. India Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Next Generation Drug Conjugates Market

11.1. Japan Next Generation Drug Conjugates Market Overview

11.2. Japan Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Next Generation Drug Conjugates Market

12.1. Australia Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Next Generation Drug Conjugates Market

13.1. Indonesia Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Next Generation Drug Conjugates Market

14.1. South Korea Next Generation Drug Conjugates Market Overview

14.2. South Korea Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Next Generation Drug Conjugates Market

15.1. Western Europe Next Generation Drug Conjugates Market Overview

15.2. Western Europe Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Next Generation Drug Conjugates Market

16.1. UK Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Next Generation Drug Conjugates Market

17.1. Germany Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Next Generation Drug Conjugates Market

18.1. France Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Next Generation Drug Conjugates Market

19.1. Italy Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Next Generation Drug Conjugates Market

20.1. Spain Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Next Generation Drug Conjugates Market

21.1. Eastern Europe Next Generation Drug Conjugates Market Overview

21.2. Eastern Europe Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Next Generation Drug Conjugates Market

22.1. Russia Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Next Generation Drug Conjugates Market

23.1. North America Next Generation Drug Conjugates Market Overview

23.2. North America Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Next Generation Drug Conjugates Market

24.1. USA Next Generation Drug Conjugates Market Overview

24.2. USA Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Next Generation Drug Conjugates Market

25.1. Canada Next Generation Drug Conjugates Market Overview

25.2. Canada Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Next Generation Drug Conjugates Market

26.1. South America Next Generation Drug Conjugates Market Overview

26.2. South America Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Next Generation Drug Conjugates Market

27.1. Brazil Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Next Generation Drug Conjugates Market

28.1. Middle East Next Generation Drug Conjugates Market Overview

28.2. Middle East Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Next Generation Drug Conjugates Market

29.1. Africa Next Generation Drug Conjugates Market Overview

29.2. Africa Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Next Generation Drug Conjugates Market Competitive Landscape And Company Profiles

30.1. Next Generation Drug Conjugates Market Competitive Landscape

30.2. Next Generation Drug Conjugates Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

31. Next Generation Drug Conjugates Market Other Major And Innovative Companies

31.1. AstraZeneca PLC

31.2. Daiichi Sankyo Company Limited

31.3. Eisai Co Ltd.

31.4. Bicycle Therapeutics plc

31.5. Zymeworks Inc.

31.6. Genentech Inc.

31.7. MacroGenics Inc.

31.8. Abzena plc

31.9. Innate Pharma S.A.

31.10. CytomX Therapeutics Inc.

31.11. ImmunoGen Inc.

31.12. Ascentage Pharma Group International

31.13. Mersana Therapeutics Inc.

31.14. Antengene Corporation Limited

31.15. Nurix Therapeutics Inc.

32. Global Next Generation Drug Conjugates Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Next Generation Drug Conjugates Market

34. Recent Developments In The Next Generation Drug Conjugates Market

35. Next Generation Drug Conjugates Market High Potential Countries, Segments and Strategies

35.1 Next Generation Drug Conjugates Market In 2029 - Countries Offering Most New Opportunities

35.2 Next Generation Drug Conjugates Market In 2029 - Segments Offering Most New Opportunities

35.3 Next Generation Drug Conjugates Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Next Generation Drug Conjugates Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Next Generation Drug Conjugates Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Peptide Receptor Radionuclide Therapy (PRRT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Ligand Mediated RNAi Conjugate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Ligand Conjugated Anti-Sense Medicine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Peptide Drug Conjugate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Next Generation Drug Conjugates Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Next Generation Drug Conjugates Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Pfizer Inc. Financial Performance
  • Table 81: Johnson & Johnson Financial Performance
  • Table 82: Merck & Co. Inc. Financial Performance
  • Table 83: AbbVie Inc. Financial Performance
  • Table 84: Novartis International AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Next Generation Drug Conjugates Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Next Generation Drug Conjugates Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Peptide Receptor Radionuclide Therapy (PRRT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Ligand Mediated RNAi Conjugate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Ligand Conjugated Anti-Sense Medicine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Next Generation Drug Conjugates Market, Sub-Segmentation Of Peptide Drug Conjugate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Next Generation Drug Conjugates Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Next Generation Drug Conjugates Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Next Generation Drug Conjugates Market, Segmentation By Next-Generation Drug Conjugates Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Next Generation Drug Conjugates Market, Segmentation By Targeting Ligand Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Next Generation Drug Conjugates Market, Segmentation By Payload Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Pfizer Inc. Financial Performance
  • Figure 81: Johnson & Johnson Financial Performance
  • Figure 82: Merck & Co. Inc. Financial Performance
  • Figure 83: AbbVie Inc. Financial Performance
  • Figure 84: Novartis International AG Financial Performance

Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Read More About Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Read More About Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Read More About Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

Read More About Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Ca...

View Report

Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Ca...

View Report

Lung Cancer Drugs Global Market Report 2025 – By Drugs (Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs), By Disease Type (Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC))...

View Report

Automotive Roof System Global Market Report 2025 – By Type (Sunroof System, Panorama Roof System, Multi-Optional Roof System, Solar Roof System, Light Weight Roof System, Inbuilt Roof System, Other Types), By Material (A...

View Report

Antibody Drug Conjugates Global Market Report 2025 – By Type (Monoclonal Antibodies, Linker, Drug/Toxin, Other Types), By Product (Adcertis, Kadcyla, Other Products), By Technology (Immunogen Technology, Seattle Genetics...

View Report

Metal Forging Global Market Report 2025 - By Type (Closed-Die Forging, Open-Die Forging, Ring Rolling), By Raw Material (Carbon Steel, Alloy Steel, Aluminum, Magnesium, Stainless Steel, Titanium, Other Raw Materials), By...

View Report

Bladder Cancer Drugs Global Market Report 2025 – By Type (Non-Muscle-Invasive Bladder Cancer, Muscle-Invasive Bladder Cancer), By Application (Low-Grade Tumors, High-Grade Tumors), By Distribution Channel (Hospital Pharm...

View Report

Anti-Infective Drugs Market - By Type (Antibiotics, Antivirals, Antifungals), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classifi...

View Report

Frequently Asked Questions

Next-generation drug conjugates refer to advanced formulations of drug conjugates designed to improve the efficacy and safety of targeted therapies. Next-generation drug conjugates utilize advanced targeting technologies and enhanced payloads to deliver potent therapies directly to disease cells with greater precision and reduced side effects. For further insights on this market, request a sample here

The market major growth driver - Rising Prevalence Of Cancer Is Driving The Growth Of The Next Generation Drug Conjugates Market. For further insights on this market, request a sample here

The next generation drug conjugates market size has grown rapidly in recent years. It will grow from $2.15 billion in 2024 to $2.47 billion in 2025 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to an increasing understanding of tumor biology, the success of early drug conjugates, increasing oncology, increasing investment and funding, and increasing patient advocacy and awareness. The next generation drug conjugates market size is expected to see rapid growth in the next few years. It will grow to " $4.41 billion in 2029 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to the growth of combination therapies, clinical research expansion, focus on rare diseases, strategic collaborations, and emerging bioinformatics tools. Major trends in the forecast period include advancements in monoclonal antibody technology, combination therapies with JAK inhibitors, artificial intelligence in drug development, development of biosimilars, and advancements in subcutaneous formulations. For further insights on this market, request a sample here

The next generation drug conjugates market covered in this report is segmented –
1) By Next-Generation Drug Conjugates Type: Peptide Receptor Radionuclide Therapy, Ligand Mediated RNAI Conjugate, Ligand Conjugated Anti Sense Medicine, Peptide Drug Conjugate
2) By Targeting Ligand Type: Amino Sugar, Lipid, Peptide, Small Molecule, Virus-Like Particles
3) By Payload Type: Oligonucleotide, Radionuclide, Peptide, Small Molecule
4) By Therapy: Monotherapy, Combination Therapy
5) By Indication: Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Other Indications Subsegments:
1) By Peptide Receptor Radionuclide Therapy (PRRT): Somatostatin Analogues, Radiolabeled Peptides
2) By Ligand Mediated RNAi Conjugate: SiRNA Ligand Conjugates, ShRNA Ligand Conjugates
3) By Ligand Conjugated Anti-Sense Medicine: Oligonucleotide Ligand Conjugates, Antisense Oligonucleotide Ligand Conjugates
4) By Peptide Drug Conjugate: Cytotoxic Peptide Conjugates, Therapeutic Peptide Conjugates For further insights on this market, request a sample here

North America was the largest region in the next generation drug conjugates market in 2024. The regions covered in the next generation drug conjugates marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the next generation drug conjugates marker are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Daiichi Sankyo Company Limited, Eisai Co Ltd., Bicycle Therapeutics plc, Zymeworks Inc., Genentech Inc., MacroGenics Inc., Abzena plc, Innate Pharma S.A., CytomX Therapeutics Inc., ImmunoGen Inc., Ascentage Pharma Group International, Mersana Therapeutics Inc., Antengene Corporation Limited, Nurix Therapeutics Inc., Tubulis GmbH . For further insights on this market, request a sample here.

Major trends in this market include Strategic Partnerships Driving Innovation In Next-Generation Drug Conjugates. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Next Generation Drug Conjugates Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon